Zydus Cadila gets final nod from USFDA to market generic seizures drug

Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Lamotrigine extended-release tablets USP in the strengths of 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg, Zydus Cadila said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2UTYx0P
via IFTTT